Protective role of carnitine in breast cancer via decreasing arginase activity and increasing nitric oxide

Cell Biology International

Volumn 31, Issue 11, 2007, Pages 1414-1419

  Erbas, Hakan ^a   Aydogdu, Nurettin ^a   Usta, Ufuk ^a   Erten, Oya ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Arginase; Breast cancer; Carnitine; Mice; Nitric oxide (NO); Ornithine

Indexed keywords

ARGINASE; CARNITINE; NITRIC OXIDE; ORNITHINE; POLYAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; MALE; MITOSIS; MOLECULAR INTERACTION; MOUSE; NONHUMAN; TISSUE LEVEL;

ANIMALS; ARGINASE; CARNITINE; MALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NITRIC OXIDE; ORNITHINE;

MUS;

EID: 34548435964     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2007.06.007     Document Type: Article

References (45)

1. Bachrach U. Polyamines and cancer: minireview article. Amino Acids 26 (2004) 307-309
2. Bonavida B., Khineche S., Huerta-Yepez S., and Garban H. Therapeutic potential of nitric oxide in cancer. Drug Resist Updat 9 (2006) 157-173
3. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 16 (2005) 481-488
4. Cederbaum S.D., Yu H., Grody W.W., Kern R.M., Yoo P., and Iyer R.K. Arginases I and II: do their functions overlap?. Mol Genet Metab 81 (2004) S38-S44
5. Chang B., Nishikawa M., Nishiguchi S., and Inoue M. l-Carnitine inhibits hepatocarcinogenesis via protection of mitochondria. Int J Cancer 113 (2005) 719-729
6. Chinard F.P. Photometric estimation of proline and ornithine. J Biol Chem 199 (1952) 91-95
7. Cortas N.K., and Wakid N.W. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 36 (1990) 1440-1443
8. Cruciani R.A., Dvorkin E., Homel P., Culliney B., Malamud S., Shaiova L., et al. l-Carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci 1033 (2004) 168-176
9. Cui S., Reichner J.S., Mateo R.B., and Albina J.E. Activated murine macrophages induce apoptosis in tumour cells through nitric oxide-dependent or -independent mechanisms. Cancer Res 54 (1994) 2462-2467
10. Dodson W.L., Sachan D.S., Krauss S., and Hanna W. Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. J Am Coll Nutr 8 (1989) 133-142
11. Durak I., Ozturk H.S., Elgun S., Cimen M.Y., and Yalcin S. Erythrocyte nitric oxide metabolism in patients with chronic renal failure. Clin Nephrol 55 (2001) 460-464
12. Edwards P., Cendan J.C., Topping D.B., Moldawer L.L., MacKay S., Copeland E.M., et al. Tumour cell nitric oxide inhibits cell growth in vitro, but stimulates tumorigenesis and experimental lung metastasis in vivo. J Surg Res 63 (1996) 49-52
13. Erbas H., Aydogdu N., and Kaymak K. Effects of N-acetylcysteine on arginase, ornithine and nitric oxide in renal ischemia-reperfusion injury. Pharmacol Res 50 (2004) 523-527
14. Farias-Eisner R., Sherman M.P., Aeberhard E., and Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci U S A 91 (1994) 9407-9411
15. Fukumura D., Kashiwagi S., and Jain R.K. The role of nitric oxide in tumour progression. Nat Rev Cancer 6 (2006) 521-534
16. Geyer J.W., and Dabich D. Rapid method for determination of arginase activity in tissue homogenates. Anal Biochem 39 (1971) 412-417
17. Gotoh T., Araki M., and Mori M. Chromosomal localization of the human arginase II gene and tissue distribution of its mRNA. Biochem Biophys Res Commun 233 (1997) 487-491
18. Griffith O.W., and Stuehr D.J. Nitric oxide synthases: properties and catalytic mechanism. Ann Rev Physiol 57 (1995) 707-736
19. Grody W.W., Dizikes G.J., and Cederbaum S.D. Human arginase isozymes. Isozymes Curr Top Biol Med Res 13 (1987) 181-214
20. Gugliucci A. Polyamines as clinical laboratory tools. Clin Chim Acta 344 (2004) 23-35
21. Harris B.E., Pretlow T.P., Bradley Jr. E.L., Whitehurst G.B., and Pretlow T.G. Arginase activity in prostatic tissue of patients with benign prostatic hyperplasia and prostatic carcinoma. Cancer Res 43 (1983) 3008-3012
22. Hedeyati S.S. Dialysis related carnitine disorder. Semin Dial 19 (2006) 323-328
23. Hofseth L.J., Hussain S.P., Wogan G.N., and Harris C.C. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 34 (2003) 955-968
24. Ishii N., Ikenaga H., Carmines P.K., Aoki Y., Ogawa Z., Saruta T., et al. High glucose augments arginase activity and nitric oxide production in the renal cortex. Metabolism 53 (2004) 868-874
25. Jansen A., Lewin S., Cattell V., and Cook H.T. Arginase is a major pathway of l-arginine metabolism in nephritic glomeruli. Kidney Int 42 (1992) 1107-1112
26. Jenkins D.C., Charles I.G., Thomsen L.L., Moss D.W., Holmes L.S., Baylis S.A., et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A 92 (1995) 4392-4396
27. Jenkinson C.P., Grody W.W., and Caderbaum S.D. Comparative properties of arginases. Comp Biochem Phys B 114 (1996) 107-132
28. Konarska L., Kolasa T., Albrecht P., and Regula A. Can arginase be a marker of the large bowel neoplasia?. Acta Biochim Pol 40 (1993) 164-166
29. Leu S.Y., and Wang S.R. Clinical significance of arginase in colorectal cancer. Cancer 70 (1992) 733-736
30. Li H., Meininger C.J., Hawker Jr. J.R., Haynes T.E., Kepka-Lenhart D., Mistry S.K., et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280 (2001) 75-82
31. Lowe D.T. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 4 (2000) 441-458
32. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
33. Malaguarnera M., Risino C., Gargante M.P., Oreste G., Barone G., Tomasello A.V., et al. Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J Gastroenterol 12 (2006) 4541-4545
34. Peluso G., Nicolai R., Reda E., Benatti P., Barbarisi A., and Calvani M. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J Cell Physiol 182 (2000) 339-350
35. Porembska Z., Luboinski G., Chrzanowska A., Mielczarek M., Magnuska J., and Baranczyk-Kuzma A. Arginase in patients with breast cancer. Clin Chim Acta 328 (2003) 105-111
36. Que L.G., Kantrow S.P., Jenkinson C.P., Piantadosi C.A., and Huang Y.C. Induction of arginase isoforms in the lung during hyperoxia. Am J Physiol 275 (1998) 96-102
37. Rebouche C.J., and Seim H. Carnitine metabolism and its regulation in micro-organisms and mammals. Annu Rev Nutr 18 (1998) 39-61
38. Rosai J. Rosai and Ackerman's surgical pathology. 9th ed. (2004), Elsevier, St. Louis
39. Salgado Oloris S.C., Dagli M.L., and Guerra J.L. Effect of beta-carotene on the development of the solid Ehrlich tumor in mice. Life Sci 71 (2002) 717-724
40. Singh R., Pervin S., Karimi A., Cederbaum S., and Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-l-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 60 (2000) 3305-3312
41. Straus B., Cepelak I., and Festa G. Arginase, a new marker of mammary carcinoma. Clin Chim Acta 210 (1992) 5-12
42. Suer Gokmen S., Yoruk Y., Cakir E., Yorulmaz F., and Gulen S. Arginase and ornithine, as markers in human non-small cell lung carcinoma. Cancer Biochem Biophys 17 (1999) 125-131
43. Tein I. Carnitine transport: pathophysiology and metabolism of known molecular defects. J Inherit Metab Dis 26 (2003) 147-169
44. Vinci E., Rampello E., Zanoli L., Oreste G., Pistone G., and Malaguarnera M. Serum carnitine levels in patients with tumoral cachexia. Eur J Intern Med 16 (2005) 419-423
45. Wu C.W., Chi C.W., Lin E.C., Lui W.Y., P'eng F.K., and Wang S.R. Serum arginase level in patients with gastric cancer. J Clin Gastroenterol 18 (1994) 84-85